Actively Recruiting
The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster
Led by Beijing Tiantan Hospital · Updated on 2026-01-27
750
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of antidepressants, which have central antinociceptive property and may offer analgesic benefits by modulating central nervous system pain pathways through increased serotonin and norepinephrine availability. Therefore, investigators hypothesize that tulodesvenlafaxine may effectively reduce the severity of HZ pain without significantly increasing adverse events.
CONDITIONS
Official Title
The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Onset of herpes zoster rash less than 90 days ago
- Moderate to severe herpes zoster pain with an average pain score of at least 4 on a Numeric Rating Scale (0 to 10)
- Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal
- Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher
- Ability and willingness to sign informed consent and comply with study requirements
You will not qualify if you...
- History of taking tulodesvenlafaxine
- Evidence of cutaneous or visceral dissemination of herpes zoster infection or ocular involvement
- History of intolerance or allergy to tulodesvenlafaxine or its ingredients
- History of systemic immune diseases, organ transplantation, or cancers
- Pregnancy or breastfeeding
- Presence of acute or chronic pain disorders other than herpes zoster
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China
Actively Recruiting
Research Team
F
Fang Luo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here